https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/gosh-brc-researchers-receive-nihr-senior-investigator-awards/
GOSH BRC researchers receive NIHR Senior Investigator awards
4 Apr 2016, 12:45 p.m.
Professors Francesco Muntoni, Jane Sowden and Helen Cross who have all been successfully appointed as new NIHR Senior Investigators.
They join Professor David Goldblatt who has been successful in his renewal application and Professors Phil Beales, Neil Sebire, Lyn Chitty and Catherine Law who are NIHR Senior Investigators. Professors Ros Smyth and Adrian Thrasher are both Emeritus Senior Investigators.
NIHR Senior Investigators represent the country’s most outstanding leaders of clinical and applied health and social care research. Senior Investigator’s form the NIHR college, a prestigious body which hosts a programme of events. Senior Investigators constitute a network of experts and the role involves providing research leadership to the NIHR Faculty.
Fourth Annual NIHR GOSH BRC Image Competition - A Moment of Discovery
The Research and Innovation Communications team at GOSH and the NIHR GOSH Biomedical Research team invite you to enter our Research and Innovation Showcase: A Moment of Discovery.
New hope to prevent blindness in children with rare genetic disease
A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialled by Clinicians at GOSH and University College London Great Ormond Street Institute of Child Health (UCL GOS ICH).
GOSH only hospital outside of North America to receive innovation funding award for AI
GOSH has been awarded the Amazon Web Services IMAGINE Grant: Children’s Health Innovation Award, to support artificial intelligence (AI) development and drive progress for children’s healthcare.
New clinical trial at GOSH gives hope to children with aggressive blood cancer
Researchers at GOSH and UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) are collaborating on a novel approach to clinical trials to give hope to children with an aggressive type of blood cancer, T-cell acute lymphoblastic leukaemia (T-ALL)